-
Something wrong with this record ?
Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice
M. Hofer, M. Pospíšil, L. Dušek, Z. Hoferová, D. Komůrková,
Language English Country Germany
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2002-06-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-03-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-06-01 to 1 year ago
- MeSH
- Adenosine analogs & derivatives pharmacology MeSH
- Adenosine A3 Receptor Agonists pharmacology MeSH
- Time Factors MeSH
- Whole-Body Irradiation adverse effects MeSH
- Cyclooxygenase 2 metabolism MeSH
- Cyclooxygenase 2 Inhibitors pharmacology MeSH
- Drug Interactions MeSH
- Survival Rate MeSH
- Mice MeSH
- Radiation-Protective Agents pharmacology MeSH
- Receptor, Adenosine A3 metabolism MeSH
- Thiazines pharmacology MeSH
- Thiazoles pharmacology MeSH
- Gamma Rays adverse effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
There exists a requirement for drugs which would be useful in therapy of an acute radiation damage of a mammalian organism. The aim of the study was to evaluate survival parameters in mice exposed to a lethal γ-ray dose of 8.5 Gy and treated with single doses of an adenosine A(3) receptor agonist, IB-MECA, or a cyclooxygenase-2 (COX-2) inhibitor, meloxicam, administered alone or in a combination early after irradiation, i.e., 0.5 and 1 h post-irradiation, respectively. The assessed parameters were the mean survival time (MST) and the cumulative percentage 30-day survival (CPS). Administrations of single intraperitoneal doses of either IB-MECA 0.5 h post-irradiation or meloxicam 1 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice. Combined administration of IB-MECA and meloxicam was found to be the only treatment statistically enhancing the parameter of CPS and to lead to the most expressive increase in MST of the experimental mice. The findings add new knowledge on the action of an adenosine A3 receptor agonist and a COX-2 inhibitor in an irradiated mammalian organism and suggest the potential of both the investigated drugs in the treatment of the acute radiation damage.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014574
- 003
- CZ-PrNML
- 005
- 20150429092321.0
- 007
- ta
- 008
- 150420s2014 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00411-013-0500-y $2 doi
- 035 __
- $a (PubMed)24263216
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Hofer, Michal $u Department of Molecular Cytology and Cytometry, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Královopolská 135, 61265, Brno, Czech Republic, hofer@ibp.cz.
- 245 10
- $a Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice / $c M. Hofer, M. Pospíšil, L. Dušek, Z. Hoferová, D. Komůrková,
- 520 9_
- $a There exists a requirement for drugs which would be useful in therapy of an acute radiation damage of a mammalian organism. The aim of the study was to evaluate survival parameters in mice exposed to a lethal γ-ray dose of 8.5 Gy and treated with single doses of an adenosine A(3) receptor agonist, IB-MECA, or a cyclooxygenase-2 (COX-2) inhibitor, meloxicam, administered alone or in a combination early after irradiation, i.e., 0.5 and 1 h post-irradiation, respectively. The assessed parameters were the mean survival time (MST) and the cumulative percentage 30-day survival (CPS). Administrations of single intraperitoneal doses of either IB-MECA 0.5 h post-irradiation or meloxicam 1 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice. Combined administration of IB-MECA and meloxicam was found to be the only treatment statistically enhancing the parameter of CPS and to lead to the most expressive increase in MST of the experimental mice. The findings add new knowledge on the action of an adenosine A3 receptor agonist and a COX-2 inhibitor in an irradiated mammalian organism and suggest the potential of both the investigated drugs in the treatment of the acute radiation damage.
- 650 _2
- $a adenosin $x analogy a deriváty $x farmakologie $7 D000241
- 650 _2
- $a agonisté adenosinového receptoru A3 $x farmakologie $7 D058909
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a cyklooxygenasa 2 $x metabolismus $7 D051546
- 650 _2
- $a inhibitory cyklooxygenasy 2 $x farmakologie $7 D052246
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a záření gama $x škodlivé účinky $7 D005720
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a radioprotektivní látky $x farmakologie $7 D011837
- 650 _2
- $a receptor adenosinový A3 $x metabolismus $7 D043684
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a thiaziny $x farmakologie $7 D013843
- 650 _2
- $a thiazoly $x farmakologie $7 D013844
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a celotělové ozáření $x škodlivé účinky $7 D014916
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pospíšil, Milan
- 700 1_
- $a Dušek, Ladislav
- 700 1_
- $a Hoferová, Zuzana
- 700 1_
- $a Komůrková, Denisa
- 773 0_
- $w MED00004025 $t Radiation and environmental biophysics $x 1432-2099 $g Roč. 53, č. 1 (2014), s. 211-5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24263216 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150429092625 $b ABA008
- 999 __
- $a ok $b bmc $g 1072155 $s 897452
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 53 $c 1 $d 211-5 $i 1432-2099 $m Radiation and environmental biophysics $n Radiat Environ Biophys $x MED00004025
- LZP __
- $a Pubmed-20150420